113 related articles for article (PubMed ID: 7873456)
21. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability.
Venturino A; Comandini D; Granetto C; Audisio RA; Castiglione F; Ross R; Repetto L
Breast Cancer Res Treat; 2000 Aug; 62(3):217-22. PubMed ID: 11072786
[TBL] [Abstract][Full Text] [Related]
22. [Clinical trial of lentaron for postmenopausal patients with advanced breast cancer].
Liu X; Song S; Jiang Z; Wu S; Yu J; Wang T
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):511-3. PubMed ID: 12485513
[TBL] [Abstract][Full Text] [Related]
23. Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer.
Noberasco C; Bajetta E; Zilembo N; Di Leo A; Cappuzzo F; Bartoli C; Bono A; Bichisao E
Oncology; 1995; 52(6):454-7. PubMed ID: 7478430
[TBL] [Abstract][Full Text] [Related]
24. Formestane as treatment of advanced breast cancer in elderly women.
Zilembo N; Buzzoni R; Celio L; Noberasco C; Ferrari L; Laffranchi A; Vicario G; Dolci S; Bajetta E
Tumori; 1994 Dec; 80(6):433-7. PubMed ID: 7900232
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning PE
Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
[TBL] [Abstract][Full Text] [Related]
27. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Nisslein T; Freudenstein J
Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
[TBL] [Abstract][Full Text] [Related]
28. Formestane for advanced breast cancer in postmenopausal women.
Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
[No Abstract] [Full Text] [Related]
29. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Carlini P; Ferretti G; Di Cosimo S; Colella E; Tonachella R; Romiti A; Tomao S; Frassoldati A; Papaldo P; Fabi A; Ruggeri EM; Cognetti F
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):107-9. PubMed ID: 12943750
[TBL] [Abstract][Full Text] [Related]
30. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
31. 4-Hydroxyandrostenedione treatment for postmenopausal patients with breast cancer.
Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):145-8. PubMed ID: 1525056
[TBL] [Abstract][Full Text] [Related]
32. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Vorobiof DA; Kleeberg UR; Perez-Carrion R; Dodwell DJ; Robertson JF; Calvo L; Dowsett M; Clack G
Ann Oncol; 1999 Oct; 10(10):1219-25. PubMed ID: 10586340
[TBL] [Abstract][Full Text] [Related]
33. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
Buzdar AU; Vergote I; Sainsbury R
Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
[TBL] [Abstract][Full Text] [Related]
34. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
35. Combined inhibitory effect of formestane and herceptin on a subpopulation of CD44+/CD24low breast cancer cells.
Cavaliere C; Corvigno S; Galgani M; Limite G; Nardone A; Veneziani BM
Cancer Sci; 2010 Jul; 101(7):1661-9. PubMed ID: 20491779
[TBL] [Abstract][Full Text] [Related]
36. 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.
Coombes RC; Goss PE; Dowsett M; Hutchinson G; Cunningham D; Jarman M; Brodie AM
Steroids; 1987; 50(1-3):245-52. PubMed ID: 3504062
[TBL] [Abstract][Full Text] [Related]
37. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
[TBL] [Abstract][Full Text] [Related]
38. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
[TBL] [Abstract][Full Text] [Related]
39. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
40. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
